## DHR: Danaher Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.3% below STRENGTH zone (3.0-6.0%); PEG 1.85 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($213.79)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Dnca Finance Sells 5,500 Shares of Danaher Corporation $DHR**
- Source: MarketBeat | 20251207T092107 | Somewhat-Bullish | Relevance: 99%
-  Dnca Finance reduced its stake in Danaher Corporation by 9.6%, selling 5,500 shares and retaining 52,000 shares valued at approximately $10.27 million. Insiders have also been net sellers, with Director Teri List and SVP Brian W. Ellis selling a combined 30,248 shares. Despite insider selling, analysts maintain a "Moderate Buy" rating with a consensus price target of $245.75, following a recent earnings beat.

**2. Danaher Announces Quarterly Dividend**
- Source: KXAN Austin | 20251209T161500 | Somewhat-Bullish | Relevance: 99%
- Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock. The dividend is payable on January 30, 2026, to shareholders of record on December 26, 2025. Danaher is a leading global life sciences and diagnostics innovator focused on improving human health through science and technology.

**3. Danaher Corporation $DHR Shares Sold by State Street Corp**
- Source: MarketBeat | 20251209T132720 | Somewhat-Bullish | Relevance: 99%
-  State Street Corp reduced its stake in Danaher Corporation (NYSE:DHR) by 0.6% in the second quarter, selling 164,456 shares and retaining 27,299,515 shares valued at $5.4 billion. Other institutional investors also adjusted their positions, with insider selling by Director Teri List and SVP Brian W. Ellis totaling over $5.5 million in the last ninety days. Analysts have a "Moderate Buy" rating on DHR, with a consensus price target of $246.79.

**4. Cresset Asset Management LLC Has $6.05 Million Stock Holdings in Danaher Corporation $DHR**
- Source: MarketBeat | 20251207T090809 | Somewhat-Bullish | Relevance: 98%
-  Cresset Asset Management LLC reduced its stake in Danaher Corporation (NYSE:DHR) by 27.2% in Q2, now holding 30,592 shares valued at approximately $6.05 million. This comes as other major institutions like Vanguard and Norges Bank have significantly increased their positions, with institutional investors now owning 79.05% of DHR stock. Danaher also beat recent earnings estimates, reporting $1.89 EPS and $6.05 billion in revenue, and maintains a "Moderate Buy" consensus rating among analysts with an average target price of $245.75.

**5. Ossiam Has $28.59 Million Stake in Danaher Corporation $DHR**
- Source: MarketBeat | 20251208T115110 | Bullish | Relevance: 98%
-  Ossiam significantly increased its stake in Danaher Corporation by 716.7% in Q2, bringing its total holdings to 144,744 shares valued at $28.59 million. Despite recent insider sales totaling over $6.6 million, Wall Street analysts maintain a "Moderate Buy" consensus rating for Danaher, with an average price target of $245.75, following its beat on quarterly EPS expectations. The company also announced a quarterly dividend of $0.32 per share, yielding 0.6% annually.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $265 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $270 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 10 ($75.99M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 8.6% (+0.2%)
- Blackrock Inc.: 7.4% (+0.1%)
- JPMORGAN CHASE & CO: 5.3% (+404.7%)
- State Street Corpora: 3.9% (-0.3%)
- Capital Internationa: 2.4% (+1.9%)

### Key Risks

1. Heavy insider selling: $76M sold (10 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.85 elevated, pricing in significant growth expectations. Forward P/E 26.5x stretched relative to 9% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($76.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $159.8B |
| Beta | 0.92 |
| 52W Range | $171.00 - $258.23 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.85 |
| Forward P/E | 26.5 |
| Current P/E | 28.9 |
| YoY Growth | 9.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-1.0% over 5 days). Below STRENGTH zone by 5.3pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-0.75), momentum weakening. RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.27% (CS: 33) | Weak |
| RSI_14 | 52.3 | Neutral |
| MACD Histogram | -0.75 | Bearish |
| vs SMA20 | 0.995x | Below |
| vs SMA50 | 1.029x | Above |
| vs SMA200 | 1.099x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $223.23
- **Stop Loss:** $213.79 (4.2% risk)
- **Target:** $232.67 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 31
- **Position Value:** $6,920.13
- **Portfolio %:** 6.92%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-28 (Est: $2.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.72 | $1.89 | +9.8% |
| 2025Q2 | $1.64 | $1.80 | +9.5% |
| 2025Q1 | $1.64 | $1.88 | +14.4% |
| 2024Q4 | $2.16 | $2.14 | -1.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*